Biogeneric APIs Showing Promising Future in the Biotech API Industry

Press Release   •   Aug 03, 2012 12:43 IST

According to a new research report by RNCOS entitled, “Global Biotech API Market Analysis”, the biogeneric APIs are expected to show faster growth than the innovator biotech APIs in the biotech API market. The loss of patent protection of several blockbuster biotech drugs in near future is the main driver for this shift. The robust growth in the usage and popularity of biosimilars, especially erythropoietin, recombinant human insulin amongst others will also bring much attention to the Generic Biotech API business.

With the growing importance of biological drugs in the market, biotech APIs are expected to account for a much higher share in the future in the overall API market.  Amongst the various geographies, the future growth is likely to emanate from the Asia-Pacific countries, such as India and China. These countries are witnessing effective advancements in the field of outsourcing business as well as in-house biotech market leading to their global staging. The biotech APIs are expected to find greater applications in the treatment of chronic killers, such as diabetes, cancer and other life-threatening diseases. Moreover, according to the latest report by RNCOS the biotech API market is expected to grow at a CAGR of around 15% from 2012-2015.

The report which is spread in over 55 pages provides an analysis of the global API and biotech API market. It provides a global break up of branded and generic API’s and synthetic and biotech API’s. Further the biotech API market has been covered along with its major market segments. The geographic break-up provides an analysis on major geographies and untapped markets. The current and future forecasts for the API market have been presented to provide the market progress in the coming years along with expected growth in the overall industry. Regulatory scenario analysis has also been provided for a holistic understanding of the industry requirements. Major focus has been laid on the key competitor assessment to present a meaningful description of the biotech API business along with an analysis on their strengths and weaknesses.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM424.htm

Some of our Related Reports are:

- EPO Biosimilars Market Forecast to 2015 (http://www.rncos.com/Report/IM392.htm)
- G-CSF Biosimilars Market Forecast to 2015 (http://www.rncos.com/Report/IM393.htm)
- HGH Biosimilars Market Forecast to 2015 (http://www.rncos.com/Report/IM394.htm)
- Global RNAi Market Analysis (http://www.rncos.com/Report/IM329.htm)
- Global Gene Therapy Market Analysis (http://www.rncos.com/Report/IM282.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm


RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.